以云南3个不同主产区具有代表性的普洱茶为样本,采用常压耐缺氧实验、亚硝酸钠中毒存活实验、急性脑缺血性缺氧实验3项指标评价普洱茶对小鼠的耐缺氧作用。结果表明,在常压耐缺氧实验中,与对照组相比,普洱熟茶中剂量组(1.5g/kg)可明显延长小鼠在密闭缺氧条件下的存活时间(P<0.05),且延长率达到12.45%;在亚硝酸钠中毒存活实验中,与对照组相比,各实验组存活时间均低于对照组;在急性脑缺血性缺氧实验中,各实验组张口喘气时间均低于对照组。研究表明,所用该批次普洱熟茶和普洱生茶对小鼠不具有耐缺氧功能。
In this study, two representative tea samples (Fermented Pu-erh and Unfermented Pu-erh), which from different main producing areas, were employed to carry out the hypoxia tolerance experiment, survival experiment of sodium nitrite poisoning and acute cerebral ischemia hypoxia experiment. Results showed: the Fermented Pu-erh, at the medium dose group (1.5g/kg), could significantly prolong the mice survival time under close hypoxia conditions, compared to the control group, the prolongation rate is 12.45% in the hypoxia tolerance experiment. The survival time of all test groups were lower than the control group in the survival experiment of sodium nitrite poisoning and in acute cerebral ischemia hypoxia experiment, respectively. Totally, Fermented Pu-erh and Unfermented Pu-erh may have no anti-anoxia ability.
[1] 周红杰. 普洱茶的特点及健身作用[J]. 茶叶, 2003, 29(2): 75-77.
[2] 曾云荣. 独具魅力的云南普洱茶[J]. 茶叶, 2004, 30(4): 237-239.
[3] 赵飞龙, 周红杰, 安文杰. 云南普洱茶保健功效的研究[J]. 食品研究与开发, 2005, 26(2): 114-118.
[4] Yang T T, Koo M W.HyPocholesterolemic effects of Chinese tea[J]. Pharmacol Res, 1997, 35(6): 505-512.
[5] 侯艳, 肖蓉, 邵宛芳, 等. 普洱茶对试验大鼠血清中血脂水平和脂质过氧化的影响[J]. 中国食品学报, 2009, 9(2): 80-85.
[6] Hiroyuki Fujita, Tomohide Yamagami.Efficacy and Safety of Chinese Black Tea (Pu-Ehr) Extract in Healthy and Hyper- cholesterolemic Subjects[J]. Ann Nutr Metab, 2008(53): 33-42.
[7] 孙璐西, 张惠泉. 普洱茶之抗动脉硬化作用[G]// 2002中国普洱茶国际学术研讨会组委会. 2002中国普洱茶国际学术研讨会论文集. 云南: 云南人民出版社, 2002: 309-317.
[8] Duh P D, Yen G C, Yen W J, et al. Effects of Pu-erh tea on oxidative damage and nitric oxide scavenging[J]. J Agrie Food Chem, 2004, 52(26): 8169-8176.
[9] Lin L C, Liuchang H C, Hwang L S, et al. The hypoliPidemie and antioxidative effects of Pu-erh tea[J]. Atheroselerosis, 1998, 56(1): 36-44.
[10] Chia-Nan Chen, Coney P C Linl, Kuo-Kuei Huang, et al. Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3, 3-digallate(TF3)[J]. Evid Based Complement Alternat Med, 2005, 2(2): 209-215.
[11] 于守洋. 中国保健食品的进展[M]. 北京: 人民卫生出版社, 2001: 54-55.
[12] 张惟杰. 糖复合物生化研究技术: 第二版[M]. 杭州: 浙江大学出版社, 1999: 185-186.
[13] 中华人民共和国卫生部. 保健食品检验与评价技术规范[S]. 北京: 中科多媒体电子出版社, 2003: 10-11.
[14] 中华人民共和国广东出入境检验检疫局. 国内外技术法规和标准中食品微生物限量[S]. 北京: 中国标准出版社, 2002: 13.